129 related articles for article (PubMed ID: 16837628)
1. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
Mhawech-Fauceglia P; Saxena R; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
J Clin Pathol; 2007 Jun; 60(6):709-14. PubMed ID: 16837628
[TBL] [Abstract][Full Text] [Related]
2. Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
Mhawech-Fauceglia P; Herrmann FR; Bshara W; Odunsi K; Terracciano L; Sauter G; Cheney RT; Groth J; Penetrante R; Mhawech-Fauceglia P
J Clin Pathol; 2007 Jun; 60(6):694-700. PubMed ID: 16917000
[TBL] [Abstract][Full Text] [Related]
3. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas.
Dong HY; Liu W; Cohen P; Mahle CE; Zhang W
Am J Surg Pathol; 2005 May; 29(5):687-92. PubMed ID: 15832095
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays.
McCune RC; Syrbu SI; Vasef MA
Mod Pathol; 2006 Jul; 19(7):1010-8. PubMed ID: 16648862
[TBL] [Abstract][Full Text] [Related]
5. Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma.
Khan MR; Ahmad A; Kayani N; Minhas K
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3463-3466. PubMed ID: 30583670
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of PAX5 and TdT by Merkel cell carcinoma and pulmonary small cell carcinoma: a potential diagnostic pitfall but useful discriminatory marker.
Kolhe R; Reid MD; Lee JR; Cohen C; Ramalingam P
Int J Clin Exp Pathol; 2013; 6(2):142-7. PubMed ID: 23329999
[TBL] [Abstract][Full Text] [Related]
8. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation.
Dong HY; Browne P; Liu Z; Gangi M
Histopathology; 2008 Sep; 53(3):278-87. PubMed ID: 18643853
[TBL] [Abstract][Full Text] [Related]
9. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.
Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H
Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034
[TBL] [Abstract][Full Text] [Related]
10. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
Desouki MM; Post GR; Cherry D; Lazarchick J
Clin Med Res; 2010 Jul; 8(2):84-8. PubMed ID: 20660931
[TBL] [Abstract][Full Text] [Related]
11. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
12. CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5.
Shukla S; Awasthi NP; Singh P; Husain N
J Cancer Res Ther; 2015; 11(3):658. PubMed ID: 26458662
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples.
Agostinelli C; Sabattini E; Gjørret JO; Righi S; Rossi M; Mancini M; Piccaluga PP; Bacci F; Marafioti T; Bettini G; Falini B; Pileri SA
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):561-72. PubMed ID: 20697266
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pax5 expression and comparison with BLA.36 and CD79αcy in feline non-Hodgkin lymphoma.
Felisberto R; Matos J; Alves M; Cabeçadas J; Henriques J
Vet Comp Oncol; 2017 Dec; 15(4):1257-1268. PubMed ID: 27549353
[TBL] [Abstract][Full Text] [Related]
15. Reactivity with TdT in Merkel cell carcinoma: a potential diagnostic pitfall.
Buresh CJ; Oliai BR; Miller RT
Am J Clin Pathol; 2008 Jun; 129(6):894-8. PubMed ID: 18480005
[TBL] [Abstract][Full Text] [Related]
16. Is fascin really a useful marker in distinguishing between classical Hodgkin's lymphoma and various types of non-Hodgkin's lymphomas in difficult cases?
Idrees R; Ahmad Z; Qureshi A; Ahsan A; Pervez S
J Clin Pathol; 2010 Jul; 63(7):571-4. PubMed ID: 20591908
[TBL] [Abstract][Full Text] [Related]
17. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
Zhang X; Lin Z; Kim I
J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
[TBL] [Abstract][Full Text] [Related]
18. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
19. Does Strong and Diffuse PAX-8 Positivity Occur in Primary Lung Carcinoma? An Immunohistochemical Study of 418 Cases and Review of the Literature.
McHugh KE; Arrossi AV; Farver CF; Mukhopadhyay S
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):140-146. PubMed ID: 28777151
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
